Catalent today announced that Paul Ingram, Ph.D., Global Director, Strategic Development and Innovation, will present at the upcoming conference, ‘Clinical Trial Supply Forum’.

Catalent today announced that it was approved by the U.S. FDA to produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy.

Catalent today announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion will be segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.

Catalent will support the development, manufacturing, and clinical supply of Editas Medicine’s portfolio of in vivo CRISPR medicines and engineered cell medicines.

Catalent today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 – 29, 2020.

Catalent today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.

Catalent and Humanigen today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab.

As a development and manufacturing partner that supplies medicines, clinical trial materials, and health products to patients and consumers, we are taking action to minimize the impact of the COVID-19 pandemic.

Catalent today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.